Nevertheless, in order to exclude the possibility that different MLL mutation frequencies resulted from different clinical characteristics, we validated the mutation status of MLL in a 40 low grade primary and 40 low grade relapsed bladder cancer samples, in which the stage ranged from Ta to T1 (Supplementary Table 6). This evidence concerns the gene KMT2A and urinary bladder carcinoma.